Moderna, Inc. (NASDAQ:MRNA) Given Consensus Rating of “Hold” by Brokerages

Moderna, Inc. (NASDAQ:MRNA) has received an average rating of “Hold” from the nineteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $100.44.

MRNA has been the topic of a number of analyst reports. Royal Bank of Canada restated a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. HSBC raised Moderna from a “reduce” rating to a “hold” rating and set a $82.00 target price on the stock in a research report on Wednesday, August 28th. Bank of America lowered their price target on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a report on Friday, September 13th. Barclays cut their price objective on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a report on Monday, September 16th. Finally, Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 689 shares of the stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total transaction of $81,467.36. Following the completion of the sale, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $117.08, for a total value of $1,756,200.00. Following the sale, the director now owns 2,269,015 shares of the company’s stock, valued at $265,656,276.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James M. Mock sold 689 shares of the stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $118.24, for a total transaction of $81,467.36. Following the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at $859,486.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 78,158 shares of company stock worth $9,259,012 in the last quarter. Company insiders own 15.70% of the company’s stock.

Hedge Funds Weigh In On Moderna

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC raised its position in Moderna by 24.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 6,495 shares of the company’s stock worth $646,000 after acquiring an additional 1,258 shares in the last quarter. Focus Financial Network Inc. ADV purchased a new position in shares of Moderna in the 4th quarter valued at about $596,000. TFO Wealth Partners LLC lifted its stake in shares of Moderna by 61,075.0% in the fourth quarter. TFO Wealth Partners LLC now owns 2,447 shares of the company’s stock valued at $243,000 after purchasing an additional 2,443 shares during the period. Bank of Nova Scotia grew its position in Moderna by 68.2% during the fourth quarter. Bank of Nova Scotia now owns 45,800 shares of the company’s stock worth $4,550,000 after buying an additional 18,574 shares during the period. Finally, Alberta Investment Management Corp increased its holdings in Moderna by 11.3% in the fourth quarter. Alberta Investment Management Corp now owns 97,725 shares of the company’s stock valued at $9,719,000 after buying an additional 9,900 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Down 1.4 %

MRNA stock opened at $60.20 on Friday. The company’s 50 day moving average price is $78.45 and its 200 day moving average price is $108.00. The firm has a market capitalization of $23.07 billion, a price-to-earnings ratio of -3.84 and a beta of 1.66. Moderna has a fifty-two week low of $59.62 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($3.62) EPS. On average, equities research analysts anticipate that Moderna will post -9.86 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.